Canada House Wellness Group Inc. Accelerates Phenotyping of 62 In-House Genetics
February 14 2019 - 6:00AM
Canada House Wellness Group Inc. (“Canada House” or the “Company”)
(CSE:CHV) and Abba Medix Corp. (“Abba”), CHV’s wholly owned
Licensed Producer has accelerated their phenotyping program
utilizing their state-of-the-art controlled grow facility in
Pickering.
Growing since May 8, 2018, Abba Medix Corp. currently has 62
strains in-house. “With our main production area fully online, we
have accelerated our phenotyping program and will continue to build
our genetics library. The pursuit of superior genetics will never
stop at Abba. Our team knows what patients and recreational
consumers expect, and we intend to deliver it,” said Riley McGee,
President, Abba Medix Corp.
Utilizing its exclusive partnership with a leading European seed
breeder, Abba has carefully curated a library of strains offering a
wide range of cannabinoid profiles. Abba will be working
closely with Canada House Clinics (CHC), leveraging their 12,000
plus patients and their proprietary Knalysis Technologies patient
management software.
“Canada House’s vertical integration has been designed from day
one to bring evidence-based strains to patients. With Canada House
Clinic’s medical professionals and diverse patient base, our
proprietary software and our state-of-the-art controlled grow
facility, we are positioned to become leaders in cannabis genetics.
2019 will be a pivotal year for Canada House Wellness Group Inc. as
we claim our spot as leaders in the space,” said Chris Churchill
Smith, CEO, Canada House.
Working closely with CHC’s highly qualified staff, Abba seeks to
better serve patients and further our understanding of cannabinoid
profiles and their respective applications.
For further information, please contact:
Boom Capital MarketsSteve
Low647-620-5101steve@boomcapitalmarkets.com
Canada House Wellness Group Inc.Chris Churchill-Smith,
CEO514-313-0102chris.smith@canadahouse.ca
ABOUT CANADA HOUSE WELLNESS GROUP INC.Canada
House is an experienced, integrated medical cannabis company
providing patient-specific cannabinoid therapy products and
services through its clinics and licensed producer. Canada House is
the parent company of Canada House Clinics Inc., Knalysis
Technologies and Abba Medix Corp. For more information, please
visit www.canadahouse.ca or www.sedar.com.
Cautionary Statement Regarding Forward Looking
Information. This press release contains forward-looking
statements, including statements that relate to, among other
things, the Company’s clinic, production and technology businesses,
its future plans, the Company’s markets, objectives, goals,
strategies, intentions, beliefs, expectations and estimates, and
can generally be identified by the use of words such as “may”,
“will”, “could”, “should”, “would”, “likely”, “possible”, “expect”,
“intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective”
and “continue” (or the negative thereof) and words and expressions
of similar import. Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable, such statements involve risks and uncertainties, and
undue reliance should not be placed on such statements.
Certain material factors or assumptions are applied in making
forward-looking statements, and actual results may differ
materially from those expressed or implied in such statements.
Material assumptions used to develop forward-looking information in
this news release include, among other things, the regulations
related to cannabis use under the Access to Cannabis for Medical
Purposes Regulations and the act respecting cannabis and to amend
the Controlled Drugs and Substances Act, the Criminal Code and
other Acts, passed by the Canadian Federal government, making
cannabis legal for recreational use by October 17, 2018; Company
liquidity and capital resources, including the availability of
additional capital resources to fund its activities; level of
competition; the ability to adapt products and services to the
changing market; the ability to attract and retain key executives;
and the ability to execute strategic plans. Additional information
about material factors that could cause actual results to differ
materially from expectations and about material factors or
assumptions applied in making forward-looking statements may be
found in the Company’s most recent annual and interim Management’s
Discussion and Analysis under “Risk and Uncertainties” as well as
in other public disclosure documents filed with Canadian securities
regulatory authorities. The Company does not undertake any
obligation to update publicly or to revise any of the
forward-looking statements contained in this document, whether as a
result of new information, future events or otherwise, except as
required by law.
Neither the CSE nor its Regulation Services Provider (as that
term is defined in the policies of the CSE) accepts responsibility
for the adequacy or accuracy of this release.
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From May 2024 to Jun 2024
Churchill Ventures Ltd (AMEX:CHV)
Historical Stock Chart
From Jun 2023 to Jun 2024